摘要: プロスタグランジンE1（PGE1）は，強力な血小板凝集抑制能，血管拡張能を持つ局所ホルモンである．平均粒径200～300 nm（ナノメートル）のo/wエマルションであるリピッドマイクロスフェアに封入した“リポPGE1”は，障害血管部位，炎症部位などの病変部位へ薬剤を効率よく送り込む“ターゲティング”効果のために，少量で効果を発揮し，副作用の低減を可能とする画期的なDDS製剤となった．リポPGE1は1988年の臨床適用以来，日本だけでなく中国・韓国を含めて，末梢動脈閉塞症をはじめ，循環障害に起因する種々症状の改善・治癒に多大な貢献をしている．
sci-hub.se 参考文章(27)
J. H. Ahn, T. Y. Kim, Y.-J. Kim, M. W. Han, T. H. Yoon, J. W. Chung, Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes. Diabetic Medicine. ,vol. 23, pp. 1339- 1343 ,(2006) , 10.1111/J.1464-5491.2006.01993.X
Tsutomu Ishihara, Miyuki Takahashi, Megumu Higaki, Mitsuko Takenaga, Tohru Mizushima, Yutaka Mizushima, Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles Pharmaceutical Research. ,vol. 25, pp. 1686- 1695 ,(2008) , 10.1007/S11095-008-9549-8
Mitsuko TAKENAGA, Yuki OHTA, Yukie TOKURA, Akemi HAMAGUCHI, Rie IGARASHI, 静注用リポプロスタグランデイン（PG）E1製剤の比較 Yakugaku Zasshi-journal of The Pharmaceutical Society of Japan. ,vol. 127, pp. 1237- 1243 ,(2007) , 10.1248/YAKUSHI.127.1237
Y. Mizushima, T. Hamano, S. Haramoto, S. Kiyokawa, A. Yanagawa, K. Nakura, M. Shintome, M. Watanabe, Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions. Prostaglandins Leukotrienes and Essential Fatty Acids. ,vol. 41, pp. 269- 272 ,(1990) , 10.1016/0952-3278(90)90141-7
L CARLSON, INTRAVENOUS PROSTAGLANDIN E1 IN SEVERE PERIPHERAL VASCULAR DISEASE The Lancet. ,vol. 308, pp. 810- ,(1976) , 10.1016/S0140-6736(76)90653-X
PRISCILLA J. PIPER, J. R. VANE, J. H. WYLLIE, Inactivation of Prostaglandins by the Lungs Nature. ,vol. 225, pp. 600- 604 ,(1970) , 10.1038/225600A0
J.J.F. Belch, P.R.F. Bell, D. Creissen, J.A. Dormandy, R.C. Kester, R.D. McCollum, Y. Mizushima, C.V. Ruckley, J.H. Scurr, J.H.N. Wolfe, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1 Prodrug, in Patients With Intermittent Claudication Circulation. ,vol. 95, pp. 2298- 2302 ,(1997) , 10.1161/01.CIR.95.9.2298
LarsA Carlson, Ingvar Eriksson, FEMORAL-ARTERY INFUSION OF PROSTAGLANDIN E1 IN SEVERE PERIPHERAL VASCULAR DISEASE The Lancet. ,vol. 301, pp. 155- 156 ,(1973) , 10.1016/S0140-6736(73)90233-X
T. Toyota, Y. Hirata, Y. Ikeda, K. Matsuoka, A. Sakuma, Y. Mizushima, Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins. ,vol. 46, pp. 453- 468 ,(1993) , 10.1016/0090-6980(93)90081-H
Hiroyuki Murota, Yorihisa Kotobuki, Noriko Umegaki, Mamori Tani, Ichiro Katayama, New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer. Rheumatology International. ,vol. 28, pp. 1127- 1135 ,(2008) , 10.1007/S00296-008-0589-5